User profiles for Gregory A Eschenauer

Gregory A. Eschenauer, Pharm.D.

Clinical Associate Professor, Department of Clinical Pharmacy, University of Michigan
Verified email at umich.edu
Cited by 2107

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

EC Somers, GA Eschenauer, JP Troost… - Clinical Infectious …, 2021 - academic.oup.com
Background Severe coronavirus disease 2019 (COVID-19) can manifest in rapid decompensation
and respiratory failure with elevated inflammatory markers, consistent with cytokine …

[HTML][HTML] Epidemiology, Clinical Characteristics and Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Infections among Solid Organ Transplant …

…, EJ Kwak, FP Silveira, RCA Massih, GA Eschenauer… - PloS one, 2012 - journals.plos.org
Background Extensively drug-resistant Acinetobacter baumannii (XDR-Ab) has emerged as
a major nosocomial pathogen, but optimal treatment regimens are unknown. Although solid …

Risk factors and outcomes associated with treatment of asymptomatic bacteriuria in hospitalized patients

…, D Osterholzer, D Nielsen, GA Eschenauer… - JAMA internal …, 2019 - jamanetwork.com
Importance Treatment of asymptomatic bacteriuria (ASB) with antibiotics is a common factor
in inappropriate antibiotic use, but risk factors and outcomes associated with treatment of …

Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes

M Nguyen, GA Eschenauer, M Bryan, K O'Neil… - … and infectious disease, 2010 - Elsevier
We undertook a retrospective cohort study describing general outcomes and specific factors
associated with positive outcomes in bacteremia due to carbapenem-resistant Klebsiella …

[HTML][HTML] Antifungal prophylaxis in liver transplant recipients

GA Eschenauer, SW Lam, PL Carver - Liver Transplantation, 2009 - Wiley Online Library
Although the overall incidence of fungal infections in liver transplant recipients has declined,
these infections still contribute significantly to the morbidity and mortality of patients with risk …

Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream …

GA Eschenauer, MH Nguyen, S Shoham… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Reference broth microdilution methods of Candida echinocandin susceptibility testing are
limited by interlaboratory variability in caspofungin MICs. Recently revised Clinical and …

Antifungal prophylaxis in lung transplant recipients

TS Patel, GA Eschenauer, LJ Stuckey… - Transplantation, 2016 - journals.lww.com
Invasive fungal infection remains a serious postoperative complication in lung transplant
recipients and is associated with significant morbidity and mortality. Although most lung …

Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study

GA Eschenauer, PL Carver, SW Lin… - Journal of …, 2013 - academic.oup.com
Objectives We studied whether fluconazole or echinocandin treatment of Candida glabrata
fungaemia results in superior outcomes. Methods A multicentre, retrospective study was …

[HTML][HTML] Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients

ME Klatt, GA Eschenauer - Journal of Fungi, 2021 - mdpi.com
Mold-active azole antifungals are commonly prescribed for the prevention of invasive fungal
infections in lung transplant recipients. Each agent exhibits a unique pharmacologic profile, …

Is fluconazole or an echinocandin the agent of choice for candidemia

GA Eschenauer, MH Nguyen… - Annals of …, 2015 - journals.sagepub.com
Objective: Candidemia is among the most common nosocomial bloodstream infections and
is associated with high mortality, increased length of hospital stay, and significant economic …